A randomized phase 3 trial shows that adding tislelizumab to first-line chemotherapy significantly extends overall survival in advanced esophageal squamous cell carcinoma. Results with three years of follow-up reinforce the durability of the benefit, positioning the PD-1 inhibitor combination as a potential new reference regimen in an otherwise difficult-to-treat segment. The study supports continued clinical focus on immuno-oncology combinations with chemotherapy for locally advanced and metastatic disease, where long-term survival endpoints are critical for payers and guideline committees. It also adds to the evidence base for tislelizumab as a backbone for combination strategies. For oncology operators and trial designers, the key takeaway is the persistence of an OS advantage beyond early response metrics. That matters for treatment sequencing and for future studies testing escalation or de-escalation around immunotherapy-plus-chemotherapy backbones. Regulatory and formulary decisions will turn on the magnitude of OS improvement, safety, and subgroup consistency as they incorporate the extended follow-up data into their benefit-risk assessments.
Get the Daily Brief